Acasti Pharma SG&A Expenses 2014-2024 | GRCE

Acasti Pharma sg&a expenses from 2014 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Acasti Pharma Annual SG&A Expenses
(Millions of US $)
2024 $7
2023 $8
2022 $10
2021 $7
2020 $8
2019 $5
2018 $3
2017 $2
2016 $2
2015 $2
2015 $
2014 $6
2014 $
2013 $4
2013 $
Acasti Pharma Quarterly SG&A Expenses
(Millions of US $)
2024-06-30 $2
2024-03-31 $2
2023-12-31 $2
2023-09-30 $2
2023-06-30 $2
2023-03-31 $3
2022-12-31 $2
2022-09-30 $2
2022-06-30 $2
2022-03-31 $2
2021-12-31 $2
2021-09-30 $3
2021-06-30 $3
2021-03-31 $2
2020-12-31 $1
2020-09-30 $1
2020-06-30 $2
2020-03-31 $2
2019-12-31 $2
2019-09-30 $2
2019-06-30 $2
2019-03-31 $2
2018-12-31 $1
2018-09-30 $1
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $1
2017-06-30 $1
2017-02-28 $1
2016-11-30 $1
2016-08-31 $1
2016-05-31 $0
2016-03-31 $0
2016-02-29
2015-12-31 $-1
2015-09-30 $1
2015-06-30 $1
2015-03-31
2014-12-31 $1
2014-09-30 $2
2014-06-30 $2
2014-03-31
2014-02-28
2013-12-31 $2
2013-09-30 $2
2013-06-30 $1
2013-03-31
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00